Immunotherapy for myeloid leukemias: Current status and future directions

Leukemia

Volumn 22, Issue 9, 2008, Pages 1658-1664

  el Shami, K ^a   Smith, B D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CANCER VACCINE; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; IMATINIB; LEUKEMIA ANTIGEN; MONTANIDE ISA 51; QS 21; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INTERFERON PRODUCTION; LEUKAPHERESIS; LEUKEMIA REMISSION; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID;

EID: 51649129479     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.148     Document Type: Review

References (60)

1. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Hematologica 1998; 83: 1104-1115.
2. Bene MC. Immunophenotyping of acute leukemias. Immunol Lett 2005; 98: 9-21.
3. Notter M, Willinger T, Erben U, Thiel E. Targeting of B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 2001; 97: 3138-3145.
4. Bruserud O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies. Leukemia 1999; 13: 1175-1178.
5. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemia cells. Blood 1992; 80: 1750-1757.
6. Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007; 360:319-326.
7. Kurzrock R, Talpaz M. The molecular pathology of chronic myelogengus leukemia. Br J Hematol 1991; 79: 34-37.
8. Kessler JH, Bres-Vlooemans-SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M et al. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 2006; 20: 1738-1750.
9. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680-2684.
10. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al Specific human cellular immunity to bcr-abl-oncogene-derived peptides. Blood 1996; 87: 3187-3392.
11. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemia cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
12. Gannage M, Abel M, Michaellet AS, Delluc S, Iambert M, Giraudier S et al. Ex vivo characterization of multiepitopic tumor specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and cellular immunotherapy. J Immunol 2005; 174: 8210-8218.
13. Pinilla-Ibarz J, Cathcart K, Krontsvit T, Soignet S, Bocchia M, Caggiano J et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint peptides generates specific immune responses. Blood 2000; 95: 1781-1787.
14. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A et al. The translocation (6;9) associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia specific dek-can mRNA. Mol Cell Biol 1992; 12: 1687-1697.
15. de The' H, Lavau C, Marchino A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
16. Downing JR, Head Dr, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC et al. An AML1/ETO fusion transcript is consistently detected by RNA based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993; 81 2860-2865.
17. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing a fusion region of the hybrid protein pml/RARalpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1375.
18. Sturrock AB, Franklin KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. J Biol Chem 1992; 267: 1193-1199.
19. Chen T, Meier R, Ziemiecki A, Fey MF, Tobler A. Myeloblastin/proteinase 3 belongs to the set of negatively regulated primary response genes expressed during in vitro myeloid differentiation. Biochem Biophys Res Commun 1994; 200: 1130-1135.
20. Muller-Berat N, Minowada J, Tsuji-Takayama K, Drexler H, Lanotte M, Wieslander J et al. The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, a myeloperoxidase as shown by immunohistochemical studies on human leukemia cell lines. Clin Immunol Immunopathol 1994; 70: 51-59.
21. Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989; 59: 959-968.
22. Borregaard N, Cowland JB. Granules of human neutrophilic polymorphonuclear leukocytes. Blood 1997; 89: 3503-3521.
23. Brouwer E, Stageman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis. Clin Exp Immunol 1994; 98: 448-453.
24. Franssen CF, Stageman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ et al. Antiproteinase 3- and myeloperoxidase-associated vasculitis. Kidney Int 2000; 57: 2195-2206.
25. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
26. Molldrem J, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N et al Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony forming units. Blood 1997; 90: 2529-2534.
27. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen A2 tertramer can be used to isolate low frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chromic myelogenous leukemia. Cancer Res 1999; 59: 2675-2681.
28. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K et al Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancer. Curr Med Chem 2006; 13: 2345-2352.
29. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
30. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499-505.
31. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 93: 286-293.
32. Gao L, Ballantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemia CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
33. Vonderheide RH, Schultze JL, Anderson KS, maecker B, Butler MO, Xia Z et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61: 8366-8370.
34. Andersen MH, Pedersen LO, Capeller B, Bröker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61 5964-5968.
35. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-576.
36. Raptis A, Clave E, Mavroudis D, Molldrem J, Van Rhee F, Barrett AJ. Polymorphism in CD33 and CD34 genes: A source of minor histocompatibility antigens on haematopoietic progenitor cells? Br J Haematol 1998; 102: 1354-1358.
37. Amrolia PJ, Reid SD, Gao, L, Schultheis B, Dotti G, Brenner MK et al Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003; 101: 1007-1014.
38. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A et al. A nanopeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigens MZ2-E. J Exp Med 1992; 176: 1453-1457.
39. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P et al BAGE: A new gene encoding an antigen recognized on human melanoma by cytolytic T lymphocytes. Immunity 1995; 2: 167-175.
40. Greiner J, Ronghoffer M, Simikopinko O, Szmaraqowska A, Huebsch S, Maurer U et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28: 1413-1422.
41. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Steveley-O'Carroll K et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphocyte progression. Blood 2001; 98: 1070-1077.
42. Sotomayor EM, Borrello I, Levitsky HI. Tolerance and cancer: A critical issue in tumor immunology. Crit Rev Oncol 1996; 7: 433-456.
43. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.
44. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-1042.
45. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005; 365: 657-662.
46. Mailaender V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165-166.
47. Letsch A, Scheibenbogen C, Busse A, Asemissen A, Schmittel WK, Hofmann L et al. Phase II trial of vaccination with WT1 peptide, GM-CSF, and KHL in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results. Abstract J Clin Oncol 2007; 25: 3800 (Abstract No. 3008).
48. Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 4460-4468.
49. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
50. Huang AY, Bruce AT, Pardoll DM, Levitsky H. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996; 183: 769-776.
51. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al Vaccination with irradiated tumor cells engineered to express granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
52. evitsky HI, Montgomery J, Ahmedzahed M, Staveley-O'Carroll K, Guarnieri F, Longo DM et al. Immunization with granulocyte-macrophage colony stimulating factor transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific immune responses and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
53. Borrello I, Sotomayor EM, Cooke S, Levitsky H. A universal granulocyte-macrophage colony stimulating factor-producing by-stander cell line for the use in the formulation of formulation of tumor cell based vaccines. Hum Gene Ther 1999; 10: 1983-1991.
54. Smith BD, Kasamon YL, Miller CB, Chia CY, Murphy K, Kowalski J et al K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients with residual disease on imatinib mesylate (IM). American society of hematology annual meeting. Blood 2005; 106: 801 a (Abstract No. 6509).
55. Kennedy-Nasser AA, Brenner MK. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol 2007; 14: 616-624.
56. Ruggeri M, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T et al. Natural killer cell alloreactivity in allogeneic transplantation. Curr Opin Oncol 2007; 19: 142-147.
57. Wodnar-Filipowicz A, Kalberer CP. Function of natural killer cells in immune defense against human leukemia. Swiss Med Wkly 2006; 136 359-364.
58. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
59. Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematological malignancies. Leuk Lymphoma 2007; 48 1676-1695.
60. Kessler T, Fehrmann F, Bieker R, Berdel WE, Mesters RM. Vascular endothelial growth factor and its receptors as drug targets in hematological malignancies. Curr Drug Targets 2007; 8: 257-268.